Drug Profile
Tusamitamab ravtansine - Sanofi
Alternative Names: IBI-126; Maytansin-loaded anti-CEACAM5 mAb; SAR '701; SAR-408701Latest Information Update: 25 Apr 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Developer Erasmus MC; Sanofi
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 12 Apr 2024 Sanofi terminates a phase I trial for Solid tumours (Metastatic disease) in USA, Spain, Turkey, France and Belgium (IV) because CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival and is not related to safety concern (NCT05429762)
- 28 Feb 2024 Sanofi withdrew a phase II trial in Breast cancer, Non small cell lung cancer and Gastric cancer (Metastatic disease, Second-line therapy or greater) in Netherlands (IV) prior to enrollment due to the decision to discontinue the candidate's global clinical development (EudraCT2022-003451-34; NCT05703555)
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie